Skip to main content

Table 1 Exogenous OLDA administration modulates circulating cytokines and chemokines during acute inflammation

From: N-Oleoyl dopamine induces IL-10 via central nervous system TRPV1 and improves endotoxemia and sepsis outcomes

Inflammatory mediator (mean ± SD) LPS + vehicle LPS + OLDA P (Mann–Whitney)
IL-1β (pg/ml) 101 ± 44 40 ± 29 0.0005χ
IL-2 (pg/ml) 9.3 ± 4.7 6.6 ± 2 0.04χ
IL-4 (pg/ml) 1.9 ± 0.24 1.7 ± 0.28 0.06
IL-5 (pg/ml) 29 ± 6.1 15 ± 8.4 0.0003χ
IL-6 (ng/ml) 927 ± 26 477 ± 196 < 0.0001χ
IL-9 (pg/ml) 165 ± 26 60 ± 28 < 0.0001χ
IL-10 (ng/ml) 2.1 ± 0.5 13 ± 7.9 < 0.0001θ
IL-12p70 (pg/ml) 26 ± 4.7 19 ± 1.8 0.0001χ
IL-13 (pg/ml) 4.7 ± 1.1 3.6 ± 0.32 0.003 χ
IL-17A (pg/ml) 4.4 ± 2 3.4 ± 1.2 0.26
IL-18 (ng/ml) 2.4 ± 0.17 2.2 ± 0.15 0.06
IL-22 (ng/ml) 19 ± 7 2.8 ± 2.3 < 0.0001χ
IL-23 (pg/ml) 21 ± 16 15 ± 17 0.0158χ
IL-27 (pg/ml) 100 ± 29 41 ± 22 < 0.0001χ
GM-CSF (pg/ml) 22 ± 2.9 15 ± 1.8 < 0.0001χ
TNF-α (ng/ml) 1.1 ± 0.33 0.61 ± 0.13 < 0.0001χ
IFN-γ (pg/ml) 13 ± 4.7 8.6 ± 1.7 0.01χ
MCP-1/CCL-2 (ng/ml) 91.3 ± 22 55.7 ± 19 < 0.0001χ
MIP-1α/CCL-3 (ng/ml) 1.2 ± 0.2 0.75 ± 0.2 < 0.0001χ
MIP-1β/CCL-4 (ng/ml) 5.8 ± 1.3 5.1 ± 2 0.52
RANTES/CCL-5 (ng/ml) 0.8 ± 0.17 0.4 ± 0.15 < 0.0001χ
MCP-3/CCL-7 (ng/ml) 1.2 ± 0.16 0.99 ± 0.1 0.0028χ
Eotaxin/CCL-11 (ng/ml) 1 ± 0.12 0.81 ± 0.09 < 0.0001χ
Gro-α/CXCL-1 (ng/ml) 12 ± 5.7 6.1 ± 4.3 0.016χ
IP-10/CXCL-10 (pg/ml) 476 ± 37 359 ± 75 < 0.0001χ
  1. Wild-type mice were treated with LPS (1 mg/kg, i.v.) and immediately thereafter with OLDA (10 mg/kg, i.v.) or vehicle (i.v.). Cytokines and chemokines were quantified in plasma at T = 2 h using Procartaplex™ immunoassay technology (Thermo Fisher Scientific) (9- to 12-week male and female, n = 11–12/group)
  2. θIndicates significant upregulation
  3. χIndicates significant downregulation